论文部分内容阅读
目的观察多西他赛联合替吉奥治疗晚期胃癌的临床效果。方法 60例晚期胃癌患者,根据随机数字表法分为对照组及观察组,各30例。对照组应用DPF方案化疗治疗,观察组应用多西他赛联合替吉奥治疗。对比两组不良反应发生率及治疗效果。结果观察组肝功能异常、口腔黏膜炎、胃肠道反应等不良反应发生率为10.00%,低于对照组的33.33%,差异具有统计学意义(P<0.05)。观察组总有效率为66.67%,高于对照组的40.00%,差异具有统计学意义(P<0.05)。结论多西他赛联合替吉奥治疗晚期胃癌对肿瘤体积的控制以及癌细胞的扩散抑制作用更明显,且不良反应发生率较低,具有应用价值。
Objective To observe the clinical effect of docetaxel combined with tigiao in the treatment of advanced gastric cancer. Methods Sixty patients with advanced gastric cancer were divided into control group and observation group according to the random number table method, 30 cases in each. The control group was treated with DPF chemotherapy and the observation group was docetaxel combined with dipyridamole. The incidence of adverse reactions and the treatment effect were compared between the two groups. Results The incidence of adverse reactions such as liver dysfunction, oral mucositis and gastrointestinal reactions in the observation group was 10.00%, which was lower than 33.33% in the control group, with statistical significance (P <0.05). The total effective rate of observation group was 66.67%, which was higher than that of control group (40.00%), the difference was statistically significant (P <0.05). Conclusions Docetaxel combined with tirofiban in the treatment of advanced gastric cancer has obvious effect on the control of tumor volume and proliferation inhibition of cancer cells, and the incidence of adverse reactions is low, which has the value of application.